This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Neyts, J. Articles by De Clercq, E. Search for Related Content PubMed PubMed Citation Articles by Neyts, J. Articles by De Clercq, E.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, September 2002, p. 2842-2847, Vol. 46, No. 9
0066-4804/02/$04.00+0     DOI: 10.1128/AAC.46.9.2842-2847.2002
Copyright © 2002, American Society for Microbiology. All Rights Reserved.

Effect of 5-Iodo-2'-Deoxyuridine on Vaccinia Virus (Orthopoxvirus) Infections in Mice

Rega Institute for Medical Research,¹ Division of Histopathology, Katholieke Universiteit Leuven, 3000 Leuven, Belgium²

Received 1 November 2001/ Returned for modification 24 January 2002/ Accepted 28 May 2002

There is a concern that there may be unregistered stocks of smallpox that can be used for bioterrorism or biological warfare. According to the WHO Advisory Committee on Variola Research, there is a need to develop strategies to treat smallpox infections should they reappear. It would also be important to have an effective drug at hand for the treatment of monkeypox disease in humans. We show here that 5-iodo-2'-deoxyuridine (IDU) is a potent inhibitor of vaccinia virus (VV) replication and that IDU inhibits VV DNA synthesis in a dose-dependent way. The in vivo protective effect of IDU was assessed in the VV tail lesion model in immunocompetent mice and in a lethal model for VV infection in SCID (severe combined immune deficiency) mice that had been infected either intranasally, intraperitoneally, or intravenously. Subcutaneous treatment with IDU at 150 and 100 mg/kg of body weight markedly reduced the number of tail lesions in immunocompetent NMRI mice. Untreated intranasally VV-infected SCID mice died at 20.8 ± 3.1 days after infection (mean ± standard deviation). Treatment with IDU (subcutaneously, 150 mg/kg/day [from day 0 to 4] and 75 mg/kg/day [from day 6 to 11]) delayed-virus induced mortality by 15 days (mean day of death ± standard deviation, 35.8 ± 6.7; P < 0.0001). This protective effect was associated with (i) an improvement of lung histology and (ii) a marked reduction in lung viral titers. IDU also delayed VV-induced mortality when mice had either been infected intraperitoneally or intravenously. Even when the start of treatment with IDU (in intraperitoneally VV-infected mice) was postponed until 2 or 4 days after infection, an important delay in virus-induced mortality was noted.

This article has been cited by other articles:

• Prichard, M. N., Keith, K. A., Johnson, M. P., Harden, E. A., McBrayer, A., Luo, M., Qiu, S., Chattopadhyay, D., Fan, X., Torrence, P. F., Kern, E. R. (2007). Selective Phosphorylation of Antiviral Drugs by Vaccinia Virus Thymidine Kinase. Antimicrob. Agents Chemother. 51: 1795-1803 [Abstract] [Full Text]  
• Prichard, M. N., Keith, K. A., Quenelle, D. C., Kern, E. R. (2006). Activity and Mechanism of Action of N-Methanocarbathymidine against Herpesvirus and Orthopoxvirus Infections.. Antimicrob. Agents Chemother. 50: 1336-1341 [Abstract] [Full Text]  
• Shearer, J. D., Siemann, L., Gerkovich, M., House, R. V. (2005). Biological Activity of an Intravenous Preparation of Human Vaccinia Immune Globulin in Mouse Models of Vaccinia Virus Infection. Antimicrob. Agents Chemother. 49: 2634-2641 [Abstract] [Full Text]  
• Neyts, J., Leyssen, P., Verbeken, E., De Clercq, E. (2004). Efficacy of Cidofovir in a Murine Model of Disseminated Progressive Vaccinia. Antimicrob. Agents Chemother. 48: 2267-2273 [Abstract] [Full Text]